Number of qualified sufferers: CDEC mentioned the uncertainty in the amount of sufferers with moderately extreme to severe hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical authorities consulted by CADTH indicated that some clients who will be labeled as obtaining gentle or average ailment could have a extreme bleeding phenot